Krystal Biotech, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Krystal Biotech, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $15.16M, a 744.15% increase year-over-year.
- Krystal Biotech, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $6.50M, a 344.66% increase year-over-year.
- Krystal Biotech, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $3.71M, a 10.34% increase year-over-year.
- Krystal Biotech, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $1.80M, a 83.12% decline year-over-year.
- Krystal Biotech, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $22.66M, a 30.06% decline from fiscal 2024.
- Krystal Biotech, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $32.40M, a 25.98% decline from fiscal 2023.
- Krystal Biotech, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $43.77M, a 524.61% increase from fiscal 2022.
- Krystal Biotech, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $7.01M.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $15.16M 10-Q · filed 2026-08-03 | |
| 2026-03-31 | $6.50M 10-Q · filed 2026-08-03 | |
| 2025-12-31 | $22.66M 10-K · filed 2026-02-17 | |
| 2025-09-30 | $3.71M 10-Q · filed 2025-11-03 | |
| 2025-06-30 | $1.80M 10-Q · filed 2026-08-03 | |
| 2025-03-31 | $1.46M 10-Q · filed 2026-08-03 | |
| 2024-12-31 | $32.40M 10-K · filed 2025-02-19 | |
| 2024-09-30 | $3.37M 10-Q · filed 2025-11-03 | |
| 2024-06-30 | $10.64M 10-Q · filed 2025-11-03 | |
| 2024-03-31 | $15.97M 10-Q · filed 2025-11-03 | |
| 2023-12-31 | $43.77M 10-K · filed 2026-02-17 | |
| 2023-09-30 | $13.51M 10-Q · filed 2024-11-04 | |
| 2023-06-30 | $25.45M 10-Q · filed 2024-11-04 | |
| 2023-03-31 | $2.21M 10-Q · filed 2024-11-04 | |
| 2022-12-31 | $7.01M 10-K · filed 2025-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |